Á¶»óÈÆ(Cho Sang-Hoon) - Soongsil University Department of Statistics and Actuarial Science
(Jeon Jong-Su) - Soongsil University Department of Statistics and Actuarial Science
±è½ÂÀÏ(Kim Seung-Il) - Yonsei University College of Medicine Department of Surgery
Abstract
The recent advent of "-omics" technologies have heralded a new era of personalized medicine. Personalized medicine is referred to as the ability to segment heterogeneous subsets of patients whose response to a therapeutic intervention within each subset is homogeneous. This new paradigm in healthcare is beginning to affect both research and clinical practice. The key to success in personalized medicine is to uncover molecular biomarkers that drive individual variability in clinical outcomes or drug responses. In this review, we begin with an overview of personalized medicine in breast cancer and illustrate the most encountered statistical approaches in the recent literature tailored for uncovering gene signatures.
Å°¿öµå
Biomarker discovery, Breast neoplasms, Individualized medicine, Predictive biomarker, Prognostic biomarker
KMID :
1134120120150030265
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
The ultimate promise of personalized medicine depends on the discovery of the personal genetic causes of diseas.